Origin

A short dipeptide (Lys-Glu) isolated from thymic tissue extracts as part of Khavinson's bioregulation program, a 'short-form' analog of longer preparations like Thymalin.

Mechanism

Stimulates differentiation of CD5+ lymphocyte precursors into mature CD4+/CD8+ T cells and promotes thymocyte proliferation (Ki-67 expression) in organotypic thymic culture; also modulates pineal lymphoid tissue differentiation.

Research summary

Evidence

Multiple small in-vitro studies from Khavinson's laboratory show Vilon stimulates T-cell/B-cell differentiation from precursors in thymic and pineal cultures. No human clinical trials with mortality or large-cohort endpoints exist for Vilon specifically; evidence comes exclusively from Russian research institutions and remains unreplicated in the West.

Evidence tier: Available in Russia and some Eastern European countries — see the methodology note for how this is assessed.

Citations

Immunomodulating effects of Vilon and its analogue in the culture of human and animal thymus cells — Sevostianova et al. 2013

Reported benefits

T-cell differentiation/maturation
immune cell proliferation
potential thymic rejuvenation

Dosing protocols reported in the literature & community

These are protocols reported by compounding pharmacies, published trials, or self-experimentation communities — not a prescription. Start low, especially for anything new.

Reported dosing protocols
Route	Reported protocol
Intramuscular or subcutaneous injection	Typical Russian dosing: 5-10 mg IM daily or alternate-day for 10 days, repeated seasonally.

Side effects

minimal documented; rare local injection-site reaction

Safety notes

Community & reddit notes (anecdotal — not clinical evidence)

Less well-known than Thymalin in Western communities; most references are Russian or translated. Availability outside Russia is limited.